| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 1.25 Billion |
| Market Size (2030) | USD 2.72 Billion |
| CAGR (2025 - 2030) | 16.81 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players-Market---MP.webp "Viral Vector Production (Research-use) Market Major Players")
*Disclaimer: Major Players sorted in no particular order |
Viral Vector Production (Research-use) Market Analysis
The Viral Vector Production Market size is estimated at USD 1.25 billion in 2025, and is expected to reach USD 2.72 billion by 2030, at a CAGR of 16.81% during the forecast period (2025-2030).
Viral vectors are essential tools in biopharmaceutical research, widely used for applications such as gene editing, vaccine development, and gene delivery. The expansion of the biopharmaceutical industry significantly drives the demand for viral vector production.
Factors such as the increasing number of clinical studies and rising technological advancements in viral vector production are expected to boost the growth of the viral vector production (research-use) market over the forecast period.
The rising prevalence of cancer significantly boosts the demand for viral vector production for research use. As cancer rates continue to rise, there is a growing need for innovative treatments and therapies. Viral vectors are essential tools in gene therapy research, which aims to develop new ways to treat or even cure cancer. For instance, according to 2024 data published by the American Cancer Society, about 2 million people in the United States are expected to be diagnosed with cancer in 2024, as compared to 1.93 million people in 2023. Thus, the expected increase in cancer creates a pressing need for advanced research and innovative treatments requiring viral vectors, significantly boosting the demand for viral vector production in the research-use market.
Furthermore, researchers have been exploring the promise of viral vectors in the research and development of vaccines and therapeutics. For instance, an April 2023 article published in Signal Transduction and Targeted Therapy highlighted that viral vector vaccines can mimic the natural infection process of certain pathogens. This approach enables these vaccines to initiate standard acute inflammation and immune recognition due to the natural generation of pathogen-associated molecular patterns (PAMPs). This mechanism not only facilitates mucosal delivery but also promotes both local-mucosal and broader systemic immunity. Such distinctive features bolster the potency of vaccines and therapies, fueling a surge in demand for viral vector production as they are crucial for developing innovative and effective treatments.
Similarly, in April 2023, researchers from the University of Massachusetts Chan Medical School published findings in the Signal Transduction and Targeted Therapy Journal, highlighting the adeno-associated virus (AAV) as a critical delivery tool for clinical gene therapy. They emphasized its low pathogenicity and ability to sustain long-term gene expression across various tissues. These findings suggest that AAV vectors could expand the applications of viral vectors beyond traditional gene therapy, potentially driving market growth by attracting new research areas and industries seeking viral vector services.
Furthermore, the rising government funding for the establishment of new companies for manufacturing viral vectors for research and clinical trials is expected to bolster the growth of the studied market over the forecast period. For instance, in February 2024, the Government of New South Wales (NSW) allocated USD 134.5 million to set up a facility at Westmead. This facility will focus on producing viral vector products for both research and clinical trials. This substantial investment not only lays a strong groundwork for the facility's enduring success but also propels growth in the market during the forecast period.
Therefore, with the establishment of viral vector manufacturing facilities and the rising number of research studies evaluating the role of viral vectors in gene therapy, the studied market is expected to grow over the forecast period. However, the high costs associated with viral vector manufacturing and challenges in scaling viral vector manufacturing capacity may pose obstacles to market expansion.
Viral Vector Production (Research-use) Market Trends
Adenoviral Vectors is Expected to Register Significant Growth Over the Forecast Period
Adenoviral vectors, derived from non-enveloped, icosahedral-shaped DNA adenoviruses, are pivotal in gene therapy and vaccine development. Their capacity to deliver therapeutic genes to target cells, coupled with the ability to carry substantial genetic payloads and infect diverse cell types, underscores their significance. Beyond therapeutic applications, researchers harness adenoviral vectors to delve into gene function, model diseases, and innovate new treatment strategies.
Factors such as the growing application of viral vectors in gene therapy and vaccine development, advancements in vector engineering, and a surge in preclinical and clinical research driven by the rising prevalence of genetic and infectious diseases are poised to propel segment growth over the forecast period.
Additionally, strategic partnerships among academic institutions, biotechnology firms, and viral vector manufacturers are streamlining production processes, spurring innovation, and broadening research applications. For instance, in July 2024, Merck entered into a non-binding Memorandum of Understanding (MoU) with Gene Therapy Research Institution Co., Ltd. (GTRI), a clinical-stage Japanese biotech company specializing in gene therapy using adeno-associated virus (AAV) vectors. GTRI plans to utilize Merck’s Sf-RVN Insect Cell Line platform for GMP production of its viral vector-based therapy targeting Parkinson’s disease. This collaboration highlights the growing need for advanced viral vector production capabilities to support the development of innovative gene therapies, further driving market growth.
Moreover, increasing investments and the introduction of new programs are driving advancements in gene therapy research, infectious disease studies, and other areas leveraging adenoviral vectors. For instance, in February 2024, Andelyn Biosciences Inc. secured a pivotal contract to produce adeno-associated virus (AAV) therapies, catering to eight rare disease programs. This move aligns with the Foundation for the National Institutes of Health's Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC).
In addition to the above context, Andelyn is set to strengthen and expand its AAV therapy processes, specifically targeting cyclic nucleotide-gated channel beta 1 (CNGB1) Retinitis Pigmentosa 45 and NPHP5 retinal degeneration. These developments underscore the momentum in gene therapy, fueled by rising investments and new program introductions, especially in areas harnessing adenoviral vectors, from gene therapy to infectious disease research.
Similarly, in October 2023, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) launched a viral vectors program aimed at developing cost-effective manufacturing processes and analytical platforms for adeno-associated virus (AAV) gene therapy vectors. Such efforts are crucial for enhancing the accessibility and efficiency of adenoviral vector production, thereby driving market growth.
The increasing adoption of AAV vectors in gene therapy programs is expected to drive comparative studies between various viral vectors, including adenoviral vectors. These studies could provide valuable insights into the strengths and limitations of different vectors, accelerating research and development in the adenoviral vectors market. Consequently, the adenoviral vectors segment is anticipated to play a significant role in driving market growth.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Witness Considerable Growth Over the Forecast Period
North America is expected to witness a significant market share in the viral vector production (research-use) market over the forecast period. Factors such as the increasing demand for gene and cell therapies, rising government funding and support for research and development, and the increasing prevalence of genetic and rare diseases among the population.
In the United States, regulatory encouragement and patient advocacy have pushed rare disease clinical research to center stage. The significant incentives on offer through the Orphan Drugs Act (the United States) have encouraged pharmaceutical and biotechnology companies to consider the development of rare disease medicines as a potentially profitable venture.
Many companies have been expanding their facilities and investing a significant amount of capital to expand the production of viral vectors in the region. For instance, in April 2023, Bristol Myers Squibb Company expanded its global cell therapy manufacturing network through its operations in Libertyville, Illinois. This expansion enables the company to produce viral vectors internally at its United States facility. By bringing viral vector production in-house, Bristol Myers not only solidifies its leadership in cell therapy but also broadens patient access to its innovative therapies. Hence, it is expected to augment the market growth over the forecast period.
Government support, particularly in funding viral vector development, plays a pivotal role in addressing the rising demand for research, therapies, and vaccines, thus driving the region's expansion. For instance, in August 2024, Innovate UK, in collaboration with the National Research Council of Canada's Industrial Research Assistance Program, allocated a joint funding of USD 1.40 million to VVector Bio, NRC, Revvity, and Abselion. This funding aims to advance the development of a next-generation cell platform for viral vector production.
Similarly, in May 2024, the Government of Canada granted USD 57 million to the University of Manitoba and the Universities of Alberta, Saskatchewan, and Calgary. This funding is designated for conducting research in vaccine and biomanufacturing. These investments underscore the importance of government support in advancing viral vector production and ensuring the development of innovative therapies and vaccines, further anticipated to propel the market growth over the forecast period.
Thus, such favorable support from the government and initiatives from the key players to cater to the rising demand for viral vectors surge the market growth in the North America region over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
Viral Vector Production (Research-use) Industry Overview
The market studied is semi-consolidated, owing to the presence of established players, emerging companies, and contract development and manufacturing organizations (CDMOs) offering specialized offerings in the market. Companies are investing in automation and scalable bioreactor systems to enhance production efficiency and reduce costs. Some market players are Merck KGaA, Lonza, Thermo Fisher Scientific Inc., FUJIFILM Diosynth Biotechnologies, and Charles River Laboratories among others.
Viral Vector Production (Research-use) Market Leaders
-
Merck KGaA
-
Lonza
-
Thermo Fisher Scientific Inc.
-
FUJIFILM Diosynth Biotechnologies
-
Charles River Laboratories
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Viral Vector Production (Research-use) Market News
- November 2024: NewBiologix unveiled its Xcell rAAV Production and Analytics Platform, aimed at assisting gene therapy firms in identifying and producing optimal rAAV candidates for both preclinical and clinical trials. Leveraging NewBiologix's proprietary Xcell Eng-HEK293 cell line, the platform provides an efficient route to produce higher-quality rAAV particles.
- June 2024: ProBio Inc, a contract development and manufacturing organization (CDMO), inaugurated a state-of-the-art 128,000 sq. foot viral vector production facility in New Jersey. This cutting-edge site boasts office, laboratory, and manufacturing spaces, all equipped with the latest technology. It specializes in the process development and current good manufacturing practice (cGMP) production of plasmid DNA and various viral vectors, including lentivirus, adeno-associated virus, and retrovirus.
Viral Vector Production (Research-use) Industry Segmentation
As per the scope of the report, viral vector production (research-use) involves the development and supply of viral vectors tailored for laboratory research, academic institutions, and biotechnology companies. These vectors are designed to transport genetic material into cells, facilitating experimental studies, preclinical research, and various scientific investigations.
The viral vector production (research-use) market is segmented by vector type, applications, end users, and geography. By vector type, the market is segmented into adenoviral vectors, lentiviral vectors, retroviral, vectors, and others. By application, the market is segmented into cell and gene therapy research, vaccine studies, and others. By end-user, the market is segmented into pharmaceutical and biotechnology companies and academic centers and research institutes. By geography, the market is divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. For each segment, the market size is provided in terms of value (USD).
| By Vector Type | Adenoviral Vectors | ||
| Lentiviral Vectors | |||
| Retroviral Vectors | |||
| Other Types | |||
| By Application | Cell and Gene Therapy Research | ||
| Vaccine Studies | |||
| Others | |||
| By End User | Pharmaceutical and Biotechnology Companies | ||
| Academic Centers and Research Institutes | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Viral Vector Production (Research-use) Market Research FAQs
How big is the Viral Vector Production Market?
The Viral Vector Production Market size is expected to reach USD 1.25 billion in 2025 and grow at a CAGR of 16.81% to reach USD 2.72 billion by 2030.
What is the current Viral Vector Production Market size?
In 2025, the Viral Vector Production Market size is expected to reach USD 1.25 billion.
Who are the key players in Viral Vector Production Market?
Merck KGaA, Lonza, Thermo Fisher Scientific Inc., FUJIFILM Diosynth Biotechnologies and Charles River Laboratories are the major companies operating in the Viral Vector Production Market.
Which is the fastest growing region in Viral Vector Production Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Viral Vector Production Market?
In 2025, the North America accounts for the largest market share in Viral Vector Production Market.
What years does this Viral Vector Production Market cover, and what was the market size in 2024?
In 2024, the Viral Vector Production Market size was estimated at USD 1.04 billion. The report covers the Viral Vector Production Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Viral Vector Production Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Viral Vector Production (Research-use) Industry Report
Statistics for the 2025 Viral Vector Production (Research-use) market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Viral Vector Production (Research-use) analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
